Zevra therapeutics enters agreement to sell its rare pediatric disease priority review voucher for $150 million

Celebration, fla., feb. 27, 2025 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its rare pediatric disease priority review voucher (prv) for gross proceeds of $150 million upon the closing of the transaction, which is expected to take place within 30 to 45 days, subject to customary closing conditions.
ZVRA Ratings Summary
ZVRA Quant Ranking